REDWOOD CITY, Calif. and
LAS VEGAS, Jan. 12, 2018 /PRNewswire/ -- Nevro Corp. (NYSE:
NVRO), a global medical device company that is providing innovative
evidence-based solutions for the treatment of chronic pain, today
announced a series of data presentations supporting the use of
HF10™ therapy for patients with chronic pain at the
21st Annual Meeting of the North American
Neuromodulation Society (NANS) taking place through January 14 in Las
Vegas.
"Our large and growing body of clinical evidence supports the
use of HF10 therapy for patients suffering from debilitating
chronic pain and looking for alternatives to opioids," said
Rami Elghandour, President and CEO
of Nevro. "With a number of studies initiated in a variety of pain
areas and indications, we are uniquely positioned to deliver on the
promise of neuromodulation by applying our best-in-class therapy to
treat a broad array of challenging disease states. In today's
environment, patients and physicians are seeking non-pharmacologic
solutions and we are committed to helping patients regain their
lives by doing this important work. "
Key presentations at NANS of studies investigating the
safety and effectiveness of HF10 therapy for potential new
indications include:
- SENZA-ULN: a prospective, multicenter clinical trial that
evaluated HF10 therapy in subjects with chronic, intractable neck
and/or upper limb pain. Patients treated with HF10 therapy
experienced significant pain reduction at 12-month follow-up for
upper limb and neck pain (an interim VAS pain score less than 2.0
cm for each pain area). The data will be presented by Kasra Amirdelfan, MD.
- SENZA-PPN: a prospective, multicenter study evaluating HF10
therapy for the treatment of peripheral polyneuropathy, with
compelling and consistent interim results at six months that have
since prompted the initiation of a large-scale randomized clinical
trial for painful diabetic neuropathy (SENZA-PDN). The data will be
presented by Sean Li, MD.
- SENZA-NSRBP: the study design of a randomized, controlled,
multicenter trial evaluating HF10 therapy for non-surgical
refractory back pain (NSRBP) will be presented. Published
feasibility study results have recently demonstrated that patients
with non-surgical refractory back pain who received HF10 therapy
experienced significant pain reduction (VAS pain score 1.0 cm) at
36 months of follow-up; additionally, these patients reduced opioid
usage from 90% at baseline to 12% at 36 months. The presentation
will be from Adnan Al-Kaisy,
MD.
"The ongoing opioid crisis demands that experts in the field of
pain medicine seek therapies that are evidence-based,
safe, effective and sustainable for those individuals
suffering with chronic pain," said Dr. B. Todd Sitzman, M.D., M.P.H., Medical Director of
Advanced Pain Therapy, PLLC, in Hattiesburg, Mississippi and president-elect,
NANS. "The 2018 North American Neuromodulation
Society's Annual Meeting showcases high-level data in the
field of pain management, including innovative neuromodulation
approaches such as HF10 therapy. I look forward to the data
presentations, which include research developed at our center
regarding potential new indications for HF10 therapy."
A full list of HF10 therapy-related talks and posters at NANS is
available here.
About Chronic Pain
Over 100 million Americans suffer from common chronic pain. It
is the primary cause of adult disability in the U.S. and is a
costly public health issue. The combined loss of productivity and
healthcare costs exceeds $600 billion
annually in the U.S. Severe pain can significantly interfere with a
person's quality of life and functionality, yet the condition is
largely under-treated and misunderstood.
About the Senza System, HF10 Therapy
The Senza system is the only SCS system that delivers Nevro's
proprietary HF10 therapy, an SCS therapy that provides electrical
pulses to the spinal cord to alleviate pain. The electrical pulses
are delivered by small electrodes on leads that are placed near the
spinal cord and are connected to a compact, battery-powered pulse
generator implanted under the skin. HF10 therapy is the only SCS
therapy indicated to provide pain relief without paresthesia and is
also the first SCS therapy to demonstrate superiority to
traditional SCS for back and leg pain in a comparative pivotal
study. Nevro's innovations in SCS, including the Senza® system and
HF10™ therapy, are covered by more than 100 issued U.S. and
international patents.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the SENZA® spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. The SENZA® system is
the only SCS system that delivers Nevro's proprietary HF10™
therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are
trademarks of Nevro.
Media Contact:
Nicole Osmer
+1.650.454.0504
Nicole@healthandcommerce.com
Investor Relations Contact:
Katherine Bock
+1.650.433.3247
ir@nevro.com
SOURCE Nevro Corp.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nevro-to-highlight-body-of-clinical-evidence-supporting-expanded-use-and-potential-new-indications-of-companys-senza-spinal-cord-stimulation-systems-delivering-hf10-therapy-at-nans-annual-meeting-300581889.html
SOURCE Nevro Corp.